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ABSTRACT 
This thesis examines the underlying mechanisms causing the severe and 
often debilitating symptoms associated with both Irritable Bowel Syndrome and 
Inflammatory Bowel Disease.  These disorders are characterized by, abdominal pain, 
bloating, constipation and diarrhea, and the symptoms are often intermittent.  The 
variable onset and offset of symptoms suggests that periodic fluctuations in body 
state or signaling may play a role in the etiology and presentation of symptoms.  
This thesis proposes that the actions of the main intestinal hormones and their 
interactions with other hormones such as estrogen and progesterone may explain 
the oscillatory nature of the symptomatology.  Spikes in the hormone progesterone 
may induce IBS-like symptoms such as cramping and constipation thereby 
representing a potential mediator of IBS symptoms.  Evaluating the hormone 
progesterone’s role in IBS and IBD may create a new target for therapeutic 
treatments. Moreover, hormonal-based therapy represents a potential means to 
treat the cause, rather than just the symptoms of IBS and IBD.   
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INTRODUCTION 
 
 Irritable Bowel Syndrome, also known as IBS, is one of the many mysterious 
syndromes within the gastrointestinal internal medicine field.  The National 
Institute of Health states that IBS has been termed a syndrome, not a disease, 
because the symptoms, although chronic, seem to come and go 
(http://digestive.niddk.nih.gov/ddiseases/pubs/ibs_ez/, 2011).  IBS, a syndrome of 
the bowel, has been termed a “functional disorder” by many physicians due to the 
fact that a clearly defined pathophysiological cause, mechanism or substrate has not 
yet been acknowledged (Oberndorff-Klein, 2004).   Because IBS cannot be diagnosed 
based upon biological parameters, IBS is diagnosed by the presence of specific 
symptoms including, but not limited to, abdominal pain, bloating, diarrhea, 
cramping and constipation (Oberndorff-Klein, 2004).   
The Mayo Clinic, one of the leading facilities in gastroenterology research, 
defines IBS as a disorder of the large intestine that causes a constellation of 
symptoms that often vary from patient to patient 
(http://www.mayoclinic.com/health/irritable-bowel-syndrome/DS00106/, 2012).  
Because many of these symptoms can often resemble those of other diseases, the 
diagnosis of IBS can prove to be quite difficult.  Physicians diagnose IBS through an 
exclusion criterion by asking a series of questions, and sometimes performing 
procedures, such as stool tests, flexible sigmoidoscopies, colonoscopies and 
endoscopies.  Once it is evident that no organic pathology exists and that the patient 
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is not suffering from one of the many diseases of the gastrointestinal tract such as 
Crohn’s disease, colonic diverticulosis or ulcerative colitis, a diagnosis of IBS may be 
introduced (Bommelaer et al., 2004).  In this way, IBS is a diagnosis by exclusion. 
 
CAUSE  
 Currently there is no accepted theory behind the cause of IBS.  Researchers 
have begun to study multiple hypotheses but defined conclusions have not yet been 
drawn.  The National Institute of Health recognizes five potential causes that are 
currently being studied by researchers.  These causes include, brain-gut signaling 
problems, colon muscle dysfunction, hypersensitive nerves in the gut, bacterial 
infections, and the overgrowth of intestinal bacteria 
(http://digestive.niddk.nih.gov/ddiseases/pubs/ibs_ez/. 2011).   Brain-gut signal 
problems are being studied in relation to their effect on bowel habits and abdominal 
pain and discomfort.  Colon muscles may dysfunction.  When the muscles of the 
colon contract too much they can cause diarrhea and abdominal cramping.  When 
the muscles of the colon do not contract sufficiently, constipation can ensue..  
Hypersensitive nerves located in the gut may directly cause the abdominal pain or 
discomfort when stool is present, an effect increased by the presence of stress or 
anxiety.  Bacterial infections such as gastroenteritis have also been noted to initiate 
the symptoms of IBS.  And lastly, the NIH denotes the overgrowth of intestinal 
bacteria, such as flora, as being a potential causative agent 
(http://digestive.niddk.nih.gov/ddiseases/pubs/ibs_ez/, 2011).   
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It is clear that physicians and scientists alike have not yet narrowed down 
what causes this debilitating syndrome.  This thesis attempts to dive deeper into the 
potential basis of syndrome and the possible reasons for the erratic fluctuations in 
symptoms seen in many of the patients suffering from IBS. 
 
Features and Symptoms 
In order to fully understand what causes IBS, it is important to understand 
how this syndrome is diagnosed, and what factors play a role in the difficulties for 
providers to come to a clear and concrete diagnosis.  Because this syndrome does 
not have a defined pathophysiological marker, symptoms serve as the primary 
means to diagnose IBS (Corazziari, 2004).  Based on the Rome Criteria, the gold-
standard and most-used criteria for IBS, a diagnosis of IBS is concluded when the 
patients symptoms have been present for at least six months, abdominal pain or 
discomfort has been present for at least three days every month for the last three 
months, and that the abdominal pain or discomfort has two or three specific 
defining features (Corazziari, 2004).  The specific features are as follows: the pain or 
discomfort lessens following a bowel movement, there is a change in how the 
patient has a bowel movement following the pain or discomfort, and following the 
pain or discomfort there is a change in stool appearance 
(http://digestive.niddk.nih.gov/ddiseases/pubs/ibs_ez/, 2011).  
The difficulty in diagnosing IBS, a syndrome usually diagnosed by exclusion, 
has led to the overall complexity of diagnosing and treating this syndrome.  The 
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general failure of a unified approach from the three major criteria has attributed to 
the differences in diagnoses.  Enrico Corazziari ascribed the failure in diagnosing IBS 
to the differences between the Rome I, Rome II and Manning criteria (Corazziari, 
2004).  Table 1 lists the three criteria for diagnosing IBS: the Manning Criteria, the 
Rome I Criteria, and the Rome II Criteria (Corazziari 2004):1 
Table 1. Diagnostic Criteria of IBS 
 
                                                          
1 Corazziari, E. (2044). Definition and epidemiology of functional gastrointestinal disorders. 
Best Practice & Research Clinical Gastroenterology. Vol 18(4), 613-631. 
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Table 1 shows that although these three different criteria have overlapping features, 
there are substantial disparities in each one of the three descriptions of the same 
syndrome.  The lack of a consensus adds confusion to the definition of Irritable 
Bowel Syndrome and what makes it different from other gastrointestinal disorders.  
Without a clear definition of IBS, it is difficult for providers to appropriately 
diagnose and treat the disease.  While this chart represents insight into why IBS has 
been such a source of confusion for both patients and providers in today’s society, it 
is only one example of the complexities behind the IBS story.  
 Along with the differing criterion used for diagnosis, the Rome Criteria 
classify the functional gastrointestinal disorders (FGID) into subcategories: 
oesophageal, gastroduodenal, bowel, biliary, anorectal, and abdominal pain 
(Corazziari. 2004).  Because many people often have overlapping disorders, 
diagnosing FGIDs by classifying them into specific subcategories may cause 
providers to disregard patients who have overlapping FGIDs (Corazziari. 2004).  
According to The Mayo Clinic, the symptoms of IBS include, but are not 
limited to, cramping, abdominal pain, bloating, gas, diarrhea, constipation and 
mucus in the stool (http://www.mayoclinic.com/health/irritable-bowel-
syndrome/DS00106/, 2011).  The Mayo Clinic addresses the fact that although IBS 
is a chronic condition, the signs and symptoms associated with this disorder often 
fluctuate.  The Mayo Clinic defines IBS is a multifactorial syndrome brought upon by 
a combination of both environmental and genetic determinants.  The heterogeneous 
nature of this disease adds to its complexity, creating a vast disparity in symptoms 
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between patients.  Without a clear indication as to why the signs and symptoms, can 
at times, worsen, or even dramatically improve to an almost undetectable level, it 
becomes almost impossible for providers to implement an effective treatment plan.  
 
 
IBS versus IBD 
 Inflammatory Bowel Disease is comprised of two diseases, Crohn’s disease 
and ulcerative colitis (Abraham et al., 2009).  Similar to IBS, the exact mechanism 
underlying these diseases is not fully understood but current evidence suggests that 
these diseases result from inflammatory responses to intestinal microbes (Abraham 
et al., 2009).  A diagnosis of Crohn’s disease occurs through colonoscopy when 
inflammation, often discontinuous, is found in the colon, ileum, and any other 
regions of the intestine (Abraham et al., 2009).  Ulcerative colitis is also diagnosed 
via colonoscopy and usually involves inflammation, often in an interrupted pattern, 
in the rectum and other parts of the colon (Abraham et al. 2009).  It is unclear how 
prominent the role of genetic factors are in these two diseases but current evidence 
suggests that there may be a stronger genetic linkage to Crohn’s disease than 
ulcerative colitis (Abraham et al., 2009).  Similar to IBS, many therapies for 
inflammatory bowel disease have failed to provide relief from many of the 
symptoms associated with both Crohn’s disease and ulcerative colitis (Abraham et 
al., 2009) Many medications for inflammatory bowel disease such as anti-TNF-alpha 
monoclonal antibodies are directed towards decreasing the inflammation but do not 
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alleviate many of the symptoms associated with these diseases such as abdominal 
pain, bloating, constipation, diarrhea and rectal bleeding  (Abraham et al., 2009).   
Irritable Bowel Syndrome has in the past been deemed a purely 
psychological disorder, but recent studies have contradicted this once accepted 
theory (Lam et al., 2011).   Post-infectious IBS, that is, IBS that is triggered by a 
gastrointestinal infection, such as gastroenteritis, has been shown to have much 
more in common with Inflammatory Bowel Disease than previously thought.  Robin 
Spiller and Ching Lam of the Digestive Research Center at Nottingham University 
have proposed that IBS should be examined with a holistic approach, just as has 
been done in the past for IBD (Lam et al., 2011).  IBS overlaps with IBD in four main 
areas: genetic factors, gut permeability dysfunctions and gut responses to 
microbiota, and symptoms (Lam et al., 2011).  IBS, a syndrome that has been 
deemed completely psychological due to the lack of pathological findings and 
markers, has recently been gaining recognition as a disease that may be 
conquerable due to its stark similarities with IBD. 
 One of the main similarities between IBS and IBD is the correlation between 
stress on the body and the symptomatic flare-ups (Lam et al., 2011).  Flare-ups are 
periods of time when the painful symptoms of either IBS or IBD are at their peak.  
Depending on the individual, flare-ups can last anywhere from ten minutes to a few 
hours.  It is the unknown mechanism behind the peaks and plateaus in symptoms 
that occur in IBS that have physicians and scientists alike perplexed.  Spiller and 
 8 
Lam offer the idea that the mechanism behind these flare-ups in both IBD and post-
infectious IBS may be closely related if not the same (Lam et al., 2011).   
 Stress, one of the main instigators, may activate flare-ups through a mast cell 
(MC) mechanism.  Animal studies have shown that mast cells are activated and 
released by stress (Lam et al., 2011).  Researchers at the University of Nottingham 
have connected this idea to humans, stating that stress causes the “activation of the 
hypothalamic pituitary axis, increased tissue myeloperoxidase and increased 
luminal T lymphocytes along with increased piecemeal degranulation of MCs and 
increased luminal tryptase which correlated with increased jejunal permeability.” 
(Lam et al., 2011). 
 Although a mechanism involving mast cells may just be just one of the many 
possible ways symptom fluctuations are activated, looking at increases and 
decreases of GI permeability may shine light onto what really causes the 
symptomatic fluctuations.  Because IBD is more established in its pathogenesis, 
examining the commonalities between IBD and IBS offers the possibility that there 
are joint mechanistic similarities.  The idea that IBD and IBS are more related in 
mechanism and pathology than previously thought may provide leverage to a better 
understanding of IBS. 
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Quality of Life 
IBS negatively impacts quality of life.  The quality of life of someone suffering 
from IBS is similar to that of someone suffering from another chronic condition such 
as severe migraines, asthma or gastro-oesophageal reflux disease (Quigley et al., 
2006).  The tremendous burden on quality of life in a patient suffering from IBS is in 
need of much more attention and evaluation.  
In an international survey including 40,000 subjects conducted by Hungin et 
al., at the University of Durham, 78% of subjects suffering from IBS reported that 
their IBS symptoms significantly affected their lives and general well being (Hungin 
et al., 2002).  
 In addition, irritable bowel syndrome sufferers reported having more 
sickness days off work in the previous 12 months: overall, they spent 3.9 days in bed 
(corresponding figure for non-sufferers, 2.7 days), 5.5 days sick off work (3.1 days), 
8.4 days seeing a doctor or nurse (5.2 days) and 10.2 days when work activities had 
to be cut short (4.8 days).  Of those who had formally been diagnosed with irritable 
bowel syndrome, 96% had shared information about their problem with others, but 
only 10% had told their employer.  Of those formally diagnosed, 60% felt that their 
condition would be with them for life and that they had a real medical condition 
(Hungin et al., 2002).   
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The hindrance of IBS on the lives of sufferers is substantial and not vastly 
recognized by either physicians or society.  Figure 1 depicts the impact IBS can have 
on various areas of life (Hungin et al., 2002)2: 
 
 
 
 
                                                          
2 Hungin APS, Whorwell PJ, Tack J, Mearins F. (2002). The prevalence, patterns and impact 
of irritable bowel syndrome: an international survey of 40,000 subjects. Alimentary 
Pharmacology and Therapeutics. Vol 17, 643-650. 
 
Figure 1. Percentage of IBS Sufferers Reporting 
Problems 
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Both sexual and physical relationships, working, traveling, eating, sleeping and 
exercise are a few of the many areas that are affected in IBS patients.  These 
negative impacts and disturbances of daily activities are responsible for the drastic 
drop in quality of life.  In order to reduce the number of people that go undiagnosed, 
and for physicians and scientists to focus on researching and creating effective 
treatments, IBS must start to be recognized as a real and serious medical condition.    
 
 
IBS On Its Own 
It is important for physicians to not just diagnose IBS by ruling out other 
similar, yet life-threatening, diseases such as colorectal cancer, but by looking at IBS 
as an entity in and of itself.  The next challenge is for physicians to provide a way to 
manage this very complicated disorder.  “Although pharmacological treatments for 
IBS are available in the EU, robust clinical evidence of their efficacy and safety are 
lacking” (Quigley et al., 2006).  Most of the treatments available for IBS concentrate 
on relieving the symptoms, often exacerbating the syndrome as a whole.  A more 
mindful approach to creating an effective treatment plan for this syndrome would 
be to focus on the possible underlying causes that give way to the symptoms.  In this 
way, providers could focus on treating the cause instead of the current approach, 
which aims to dampen the intensely fluctuating symptoms without concern for their 
future impact. 
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Treatments 
The NIH claims that although Irritable Bowel Syndrome can be painful, often 
disrupting daily activities, the signs and symptoms of IBS do not damage the 
gastrointestinal tract (http://digestive.niddk.nih.gov/ddiseases/pubs/ibs_ez/, 
2011).   Often, patients suffering from IBS are dismissed by their physicians due to 
the lack of knowledge and scientific validation surrounding the underlying 
mechanisms of this syndrome (Occhipinto et al., 2012).  Based on current theories 
that IBS may be related to IBD much more than previously thought there may be 
some concern that IBS may not just be a purely symptomatic, benign syndrome, but 
instead, a syndrome that may lead to damaging results down the line such as 
increased risk for colorectal cancers (Lam et al., 2011). 
In order to present novel therapies for patients suffering from severe IBS, 
one must first take a look at the current therapeutic options.  Because this syndrome 
is not understood on the pathologic level, the therapies prescribed are usually 
targeted to relieve individual symptoms (Camilleri et al., 2009).  Current therapies 
usually target one of four main areas of symptomatic concern: constipation, 
diarrhea, gas and bloating, and pain (Camilleri et al., 2009).  Symptoms of 
constipation, diarrhea, and gas and bloating can all be targeted via various 
therapies, each having three lines of therapeutic agents.  The first line of therapeutic 
agents for constipation relief includes fiber capsules, laxatives and stool softeners.  
The second line of therapeutic agents includes stimulant laxatives such as Bisacodyl 
and Lubiprostone, while the third line of agents includes Linaclotide and serotonin 
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(5-HT) agonists (Camilleri et al., 2009).   Diarrhea can be treated by Loperamide and 
Diphenoxylate which are part of the first line treatment, and also by Alosetron, bile 
acid sequestrant and Clonidine, a group of smooth muscle antispasmodics (Camilleri 
et al., 2009).  The symptoms of gas and bloating can also be treated by two lines of 
therapies, but these treatments overlap treatments for many of the other symptoms.  
The first line of treatment for gas and bloating is the same method that treats the 
constipation while the second line of treatment is through the use of probiotics, 
whose effectiveness has yet to be fully evaluated (Camilleri et al., 2009). 
While the symptoms of constipation, diarrhea, and gas and bloating seem to 
have defined therapeutic agents, the most devastating symptom of pain lacks 
effective therapeutic agents.  Those suffering from IBS pain are often prescribed 
antidepressants and antipsychotics such as Anxiolytic, Duloxetine, Clonidine and 
Pregabalin (Camilleri et al., 2009).  These drugs are prescribed to symptomatic IBS 
patients because the drugs affect anxiety and mood disorders and therefore can 
sometimes have positive effects on the visceral sensation of the gut (Camilleri et al., 
2009).  Although these drugs are often prescribed to patients suffering from painful 
IBS, their efficacy has yet to be proven (Camilleri et al., 2009).  The National Institute 
of Diabetes and Digestive and Kidney Disorders also sites psychological therapy, 
such as talk therapy and gut-direct hypnotherapy as potential therapies to reduce 
IBS pain (http://digestive.niddk.nih.gov/ddiseases/pubs/ibs_ez/, 2011).   
Johns Hopkins Medicine Section of Gastroenterology and Hepatology 
represent the symptomatic management of IBS through the following chart that 
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describes the various therapies available for patients diagnosed with IBS 
(http://www.hopkinsgi.org/GDL_Disease.aspx?CurrentUDV=31&GDL_Cat_ID=AF79
3A59B73642CB9E1FE79D2B9FC358&GDL_Disease_ID=F5E21D6B-A88E-44F9-
900F-7E295C50D38B, 2001-2013)3:  
 
 
 
                                                          
3 John Hopkins Medicine of Gastroenterology and Hepatology. (2001-2013). Irritable bowel 
syndrome (IBS): therapy.  
http://www.hopkinsgi.org/GDL_Disease.aspx?CurrentUDV=31&GDL_Cat_ID=AF793A59
B73642CB9E1FE79D2B9FC358&GDL_Disease_ID=F5E21D6B-A88E-44F9-900F-
7E295C50D38B. 
 
Figure 2. Summary of the Management of Irritable 
Bowel Syndrome 
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Figure 2 depicts the tremendous emphasis that is placed on therapies that 
take a symptomatic approach.  Lifestyle modifications, psychosocial therapies and 
symptom directed therapies are all treatments that focus on alleviating the 
symptoms of IBS rather than the causes.  Serotonergic drug therapy such as 
Alosetron and Tegaserod are novel therapies for IBS that are currently being 
studied and act to reduce visceral sensitivity and gust sensation while also slowing 
colonic transport and motility 
(http://www.hopkinsgi.org/GDL_Disease.aspx?CurrentUDV=31&GDL_Cat_ID=AF79
3A59B73642CB9E1FE79D2B9FC358&GDL_Disease_ID=F5E21D6B-A88E-44F9-
900F-7E295C50D38B, 2001-2013).  These drugs mark the beginning of treatment 
therapies that target some of the potential causal mechanisms, and not just the 
symptoms, associated with IBS. 
Although these therapies may relieve painful IBS symptoms for periods of 
time, they are therapies created primarily for different diseases, and can carry a 
high risk of causing serious adverse effects.  Their long-term effectiveness has yet to 
be evaluated, and these drugs should be taken with extreme caution.  It is important 
to attempt to develop therapies that target the underlying mechanisms of painful 
IBS rather than just targeting the symptoms (Trinkley et al., 2010) so that novel 
therapies are created that are causally directed and based on targeting the 
mechanism of the disorder (Anderson et al., 2011). 
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Epidemiology  
 Dr. Sarah Payne from the University of Bristol in the United Kingdom 
estimated that nearly forty percent of the population in the United Kingdom suffers 
from many of the symptoms of irritable bowel disease (Payne, 2004).  The high 
prevalence of IBS was also found in developing countries with a documented forty-
four percent of people in Nigeria and twenty-five percent in Bangladesh suffering 
from IBS-type symptoms (Payne, 2004).  A recent primary care study in the United 
Kingdom concluded that on average, a primary care general practitioner would see 
eight IBS patients every week (Oberndorff-Klein, 2004).    
 K.E Trinkley et al., from the Ohio State University stated that IBS, although 
mostly undiagnosed, might affect nearly 15% of the population in The United States 
(Trinkley et al., 2010).  Trinkley also states that IBS is responsible for three to five 
million office visits a year, adding up to 45 billion dollars in healthcare every year.  
The reason these costs skyrocket is due to the inability of healthcare professionals 
to effectively manage the symptoms of IBS (Trinkley et al., 2010). 
 Figure 3 compares health-care utilization between patients with severe IBS 
versus patients with moderate IBS.  It is clear from this chart that patients with 
severe IBS utilize health care much more frequently due to their painful and 
disruptive symptoms as compared to patients with moderate IBS (Drossman, 
1999)4: 
                                                          
4 Drossman, D. (1999). Do psychosocial factors define symptom severity and patients status 
in irritable bowel syndrome? American Journal of Medicine. Vol 107(5), 41-50. 
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Patients self diagnosed their IBS as either severe or moderate and answered five 
quantitative questions regarding the amount of days they spend in bed over a three 
month period of time, the amount of physician visits they attend in a three month 
period of time, the amount of surgeries they have had over their lifetime due to their 
IBS condition, the amount of phone calls they made to their physician over a three 
month period of time and the number of hospital admissions due to their condition 
over a two year period (Drossman, 1999).  The amount of days in bed, visits and 
                                                                                                                                                                             
 
Figure 3. Health Care Utilization of IBS Sufferers 
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phone calls to physicians, lifetime surgeries, and hospital admissions, were 
significant and extremely high for patients suffering from severe IBS.  The inability 
to treat the painful symptoms of IBS effectively and efficiently can take a toll on not 
just the healthcare system, but society as a whole (Drossman, 1999).  Without 
effective treatment for IBS, these patients’ symptoms, their care and quality of life is 
sure to suffer. 
 
 
Gender Disparities  
 In order to begin to understand the pathology and mechanisms behind the 
painful and disruptive symptoms of IBS, it is necessary to look at the population of 
people that are affected the most. 
IBS does not seem to be related to ethnicity or race (Chang et al., 2006), but 
appears to be correlated with gender.  Women are two times more likely than men 
to be diagnosed and treated for IBS.  A community based study from Northern India 
showed the prevalence of IBS in men versus women (Makharia, 2011)5: 
 
 
 
                                                          
5 Makharia GK, Verma AK, Amarchand R, Goswarmi A, Singh P, Agnihotri A, Suhail F, 
Krishnan A. (2011). Prevalence of irritable bowel syndrome: a community based 
study from northern India. Journal of Neurogastroenterology and Motility, 17(1):82-
7 
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Figure 4 shows the drastic distinction between the numbers of men and 
women that suffer from IBS even when sampling just a small community in 
Northern India.  IBS-D is characterized as the man symptom being diarrhea, IBS-C is 
characterized as the main symptom being constipation, IBS-M is characterized as a 
mix of symptoms, and IBS-U is characterized as alternating symptoms (Makharia, 
2011).  This study showed that the women from the community had a significantly 
higher prevalence of IBS as compared to the men, but that there were no significant 
differences in the prevalence of various IBS subtypes (IBS-U, IBS-C, IBS-D, IBS-M) 
between the men and women (Makharia, 2011). 
Figure 4. Prevalence of IBS in Men Versus Women 
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Not only do women suffer more from IBS than men, but women with IBS are 
more likely to report dysmenorrhea and premenstrual distress syndrome as 
compared to women who do not suffer from IBS (Heitkemper et al., 2006).   This 
may suggest that there is a connection between the pain experienced during IBS and 
the hormones that surge throughout the menstrual cycle.   
One of the reasons that a higher percentage of women are diagnosed with 
IBS as compared to men is because women are more likely to seek provider services 
and care for functional gastrointestinal conditions (Heitkemper et al., 2008).  
Another reason why IBS is disproportionately diagnosed in women as compared to 
men is due to the potential effect of the menstrual cycle on IBS symptoms such as 
transit and motility.   The hormone progesterone, a main player in the menstrual 
cycle hormone fluctuation patterns, acts in an inhibitory manner on the smooth 
muscle of the colon (Gill et al., 1985).  Women suffering from IBS are more likely to 
seek services for constipation, while men are more likely to seek services for 
diarrhea (Heitkemper et al., 2008).  These findings suggest that the spike in 
progesterone seen a few weeks before menses may be influencing or even 
exacerbating the symptom of constipation.   
Ovarian hormones such as estrogen and progesterone may alter gut motility 
and visceral hypersensitivity, causing or worsening the painful symptoms often 
documented in IBS (Heitkemper et al., 2006).  Although the gender related 
differences seen in IBS are likely multifactorial involving environmental, 
psychological, genetic and biological factors, the event of gonadal maturation 
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coinciding with the onset of painful IBS symptoms suggests that these two events 
are not independent (Heitkemper et al., 2008).   
Overall there is a great deal of emerging evidence that suggests that the 
menstrual cycle may play a major role in the generation and onset of IBS symptoms.  
The next section will attempt to examine the relationship between the menstrual 
cycle and the onset of IBS symptoms in women.  
 
 
The Menstrual Cycle and Symptoms of IBS 
The gender difference associated with IBS often begins during early puberty, 
increases during the adult years and then slowly levels off.  The prevalence in IBS in 
older men compared to older women does not seem to be different (Heitkemper et 
al., 2008).  This fluctuation in IBS symptoms mirrors that of a woman’s menstrual 
cycle.  Menses begins at puberty and are halted when women enter their fifties and 
sixties during menopause.  The drastic symptomatic discrepancy between men and 
women appears during the period of time when women begin to ovulate, and ceases 
when women enter into menopause.   
The following figures show how the painful IBS symptoms are amplified 
during the time of a woman’s menstrual cycle (Giamberardino et al., 1997)6: 
                                                          
6 Giamberardino MA, Berkley KJ, Lezzi S, et al. (1997). Pain threshold variations in somatic 
wall tissues as a function of menstrual cycle, segmental site and tissue depth in non-
dysmenorrheic women, dysmenorrheic women and men. Pain. Vol 71(2), 187-197. 
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Figure 5. Abdominal Pain Fluctuations During Menses 
Figure 6. Bloating Symptom Fluctuations During 
Menses 
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Figure 7. Constipation Symptom Fluctuations During Menses 
 
Figure 8. Diarrhea Symptom Fluctuations During Menses 
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These figures compare the influence of menstrual hormones on pain related 
symptoms between women who suffer from IBS and women who do not.  Figure 5 
compares abdominal pain between the two cohorts of women.  Figure 6 compares 
the symptom of bloating between the two cohorts.  Figure 6 compares the level of 
constipation experienced by the two cohorts of women, and Figure 7 compares the 
level of diarrhea experienced during the menstrual cycle between the two cohorts of 
women.  The mean abdominal pain, bloating, and constipation that both cohorts of 
women experience follow the same fluctuation patterns but the women suffering 
from IBS show a dramatically elevated mean pain level as compared to the control 
women.  This study suggested that the symptom of diarrhea in women suffering 
from IBS actually decreased during the period of time following the LH surge when 
progesterone levels are high (Giamberardino et al., 1997).  This would suggest that 
progesterone plays a role in further inducing abdominal pain and bloating by 
exacerbating constipation and inhibiting diarrhea (Giamberardino et al., 1997). 
These studies suggest that estrogen and progesterone, the predominant hormones 
that are elevated following the LH surge of the menstrual cycle, may play very large 
roles in modulating the painful symptoms experienced in women suffering from IBS 
(Heitkemper et al., 2001). 
With the onset of menses comes the steep increase in estrogen and 
progesterone, possibly responsible for the severe symptomatic disparity seen 
amongst men and women during this period of time.  Heitkemper et al., discusses, 
“The variability in reproductive hormones across the menstrual cycle as well as the 
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decrease in ovarian function at menopause may serve as important factors 
influencing GI motility and visceral sensitivity.”  This suggests that GI motility and 
visceral sensitivity, which are key contributors to the symptomatic painful IBS 
experience by those suffering from IBS, may be influenced by the hormone level 
fluctuation that occurs during a woman’s menstrual cycle (Heitkemper et al., 2008). 
 
 
Objective 
 The purpose of this thesis is to delve deeper into the mechanisms behind 
Irritable Bowel Disease and propose various hormones as possible key players 
behind the mystery of symptom fluctuations and gender disparities in those 
suffering from IBS.  Understanding the interplay between specific hormones and the 
symptoms associated with IBS will allow physicians and scientists to create novel 
therapies to target the mechanism behind the fluctuations rather than just taking a 
superficial approach and relieving the symptoms instead of the underlying 
problems.   This paper will discuss in detail the gastrointestinal and ovarian 
hormones, their interplay, and ways in which these hormones may be significantly 
influencing the symptom fluctuations of IBS.  The intended effect of this information 
is to enhance our knowledge of the gastrointestinal environment that gives way to 
IBS, allowing us to create therapies through future research that may alleviate the 
underlying mechanisms that cause the painful symptoms associated with IBS, 
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thereby greatly increasing the quality of life for millions of individuals across the 
world. 
 
 
Introducing The Gastrointestinal Hormones 
 The functions of the gastrointestinal tract are regulated by endocrine, 
paracrine and neurocrine hormones (Johnson, 2001).  While the gastrointestinal 
tract may not be the first area of the body that comes to mind when one thinks 
about hormones, the gastrointestinal tract is actually home to many hormones 
(Preston, 1985).  Although there are a multitude of hormones that play roles in the 
gastrointestinal tract, this thesis will focus on five main gastrointestinal hormones.  
Secretin, gastrin, cholecystokinin, gastric inhibitory peptide, and motilin are five 
hormones that act primarily in the gastrointestinal tract, and whose actions may 
contribute to some of the many symptoms associated with IBS.  Looking at these 
hormones and better understanding their applications throughout the gut may 
provide us with a better overall picture in what mediators may be influencing gut 
dysfunction; and whether or not they may play a role in many of the symptoms of 
IBS. 
 Secretin was the first gut hormone to be discovered in 1902 by Bayliss and 
Starling (Johnson, 2001).  Secretin is a hormone dispelled by hydrochloric acid in 
the duodenal mucosa and has the unique ability to stimulate pancreatic bicarbonate 
and fluid secretion (Johnson, 2001).  Gastrin, the second gut hormone to be 
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discovered, aids in the digestion and absorption of food in the stomach by 
stimulating secretory cells (Rai, 2012).  The presence of fat in the intestine 
stimulates the hormone CCK (cholecystokinin) to initiate the contraction of the gall 
bladder (Johnson, 2001).   CCK is released from the small intestine and stimulates 
pancreatic enzyme secretions (Rai, 2012).  Gastric inhibitory peptide (GIP) is 
another hormone of the gut that is released from the intestinal mucosa in response 
to fat and glucose to inhibit gastric secretion (Johnson, 2001).  The last hormone 
that we will discuss is motilin, a crucial hormone within the gastrointestinal system.  
Motilin, a 22-amino acid peptide that primarily resides in the upper part of the small 
intestine is the main hormone responsible for gastrointestinal motility (XH, 1993).  
Motilin is also one of the hormones that is responsible for further proving the 
connection between the brain and the gut, because the actions of motilin are driven 
by neural control (XH, 1993).  
 
Secretin 
 Secretin, the polypeptide hormone that is responsible for pancreatic 
bicarbonate and fluid secretion has the following molecular structure 
(http://www.chemblink.com/products/17034-35-4.htm)8: 
                                                          
7 ChemBlink. (2013). Online database for chemicals around the world. Secretin. 
http://www.chemblink.com/products/17034-35-4.htm.  
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Figure 9.  The Molecular Structure of Secretin 
 
Secretin, as shown above in figure 9, has 27 amino acids and is part of a group of 
peptides that include the homologous structures of vasoactive intestinal peptide 
(VIP), GIP and glucagon (Johnson, 2001).  Secretin does not have one active 
segment, but instead, the entire molecule is needed in order for secretin to function 
properly (Johnson, 2001).  Because GIP and VIP have homologous structures to 
secretin, many of their actions are similar, overlap and act in identical manners 
(Johnson, 2001).    Both secretin and GIP inhibit acid secretions but while GIP only 
stimulates insulin release, secretin has many stimulating effects (Pfaffl, 2003).   
Secretin stimulates pancreatic bicarbonate secretion, bile bicarbonate secretion, and 
pancreatic growth (Johnson, 2001).    
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While certain hormones such as gastrin and motilin increase the contractions 
of the stomach, secretin and GIP inhibit these contractions.  The caudad region of 
the stomach that has contractions that increase in force and velocity as they 
approach the gastroduodenal junction (Hellstrom, 2009).  Secretin also has 
inhibiting effects on the contractions of the small intestine but its exact role in the 
motility of the small intestine has yet to be fully evaluated (Pfaffl, 2003).   The 
inhibition or stimulation of contractions of the small intestine may be a factor in 
intestinal motility dysfunction.  
 
 
Gastrin 
 Unlike secretin, which requires the entire structure to be effective, the four C-
terminal amino acids of gastrin are the critical functional portion (Johnson, 2001).   
Gastrin’s five C-terminal amino acids are identical to those of CCK, and therefore, 
these two hormones can activate each other’s receptors (Johnson, 2001).   While 
secretin, CCK, GIP, and motilin are mostly concentrated in the duodenum and 
jejunum, gastrin is primarily active in the antral and duodenal mucosa (Johnson, 
2001).  Gastrin along with the hormone motilin are the only gut hormones that are 
released strictly by neural stimulation (Johnson, 2001).  The primary actions of 
gastrin are to stimulate the release of gastric acid secretion and to stimulate 
mucosal growth (Hellstrom, 2009).  Gastrin also plays a role in the contractions of 
the smooth muscle that lines the stomach and the intestine.  Whereas secretin plays 
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a role in inhibiting the smooth muscle contractions, gastrin and motilin increase the 
contractions (Johnson, 2001).   
 There are many factors that control the motility of the small and large 
intestines.  Interstitial smooth muscle cells, enteric nerves, extrinsic nerves, and 
circulating or locally released chemicals are some of the many factors that may 
contribute to the increases and decreases in intestinal motility (Hellstrom, 2009).  
The gastroileal reflex, the term that describes the relaxation of the sphincter and the 
increase in contractility of the ileum following a meal, is mediated and stimulated 
primarily by both gastrin and CCK (Johnson, 2001).  Many of the other gut hormones 
such as somatostatin, secretin and GIP all inhibit either gastrin release or acid 
secretion (Johnson, 2001).   
Gastrin is a hormone released into the circulation following a meal along 
with other hormones such as secretin and CCK (Johnson, 2001).  The release of 
gastrin induces a multitude of digestive organ functions such as propulsive 
contractions and increases in splanchnic blood flow (Johnson, LR. 2001).  Gastrin’s 
structure is almost identical to the structure of CCK (Rai et al., 2012).  Figure 10 
shows the structure of both Gastrin and CCK, two hormones that belong to the same 
gastrointestinal family of peptides that regulate functions in both the 
gastrointestinal tract and the central nervous system (Rai et al., 2012)9: 
 
                                                          
9
 Rai R, Chandra V, Tewari M, Kumar M, Shukla H. (2012). Cholecystokinin and gastrin receptors 
targeting in gastrointestinal cancer. Surgical Oncology. Vol 21:4, 281-292. 
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Figure 10.  Molecular Structure of CCK and Gastrin 
 
Figure 10 depicts how closely related Gastrin and CCK are structurally.  Although 
these hormones take on different roles throughout the body, they share the same C-
terminal pentapeptide sequence (Rai et al., 2012).  As previously states, Gastrin, the 
hormone produced by the endocrine G-cells of the gastric antrum, stimulates acid 
secretion in the stomach, the exocrine pancreas and the large and small intestinal 
mucosa growth, while CCK, synthesized in the small intestine and cerebral neurons, 
has a variety of functions that vary from those of Gastrin (Rai et al., 2012). 
 
 
CCK 
 Shortly after the discovery of Gastrin, the hormone that initiates gallbladder 
contractions was discovered in 1928 (Johnson, 2001).  This hormone was named 
cholecystokinin because of its primary function, and that it is the presence of fat in 
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the intestine that stimulates CCK to begin acting (Johnson, 2001).  Because CCK and 
Gastrin are so similar structurally, they have the unique ability to activate each 
other’s receptors (Johnson, 2001).  That is, CCK can activate the receptors for acid 
secretion and Gastrin can activate the receptors for gallbladder contractions 
(Johnson, 2001).  Along with the contraction of the gallbladder, CCK stimulates 
pancreatic secretion, intestinal motility, cell growth, gene expression and protein 
synthesis (Rai et al., 2012).  Because CCK functions in a variety of ways it has 
receptors all over the body such as the gallbladder smooth muscles, gastric mucosa 
cells, pancreatic acinar cells, stomach and other areas in both the central and 
peripheral nervous systems (Rai et al., 2012).  CCK has also been demonstrated to 
stimulate the release of other hormones such as glucagon while also inhibiting 
gastric emptying (Johnson, 2001).  CCK, along with gastrin, have been shown to 
cause increases in colonic motility, and CCK has also been shown to increase rectal 
sensitivity to pain during periods of distension (van der Schaar et al., 2013).  Along 
with the increased sensitivity to pain, CCK has been presented as a hormone that 
may be involved in the symptoms associated with IBS.  Evidence has suggested that 
abnormal colonic motility, due to its generation of increased intraluminal pressure, 
can lead to diverticular formation (Johnson, 2001).  Because CCK plays a large role 
in the transit motility just as gastrin does, there may be a correlation between the 
functions and effects of CCK, gastrin, secretin, which inhibits intestinal motility, and 
the symptoms associated with IBS (Johnson, 2001).   
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Gastric Inhibitory Peptide 
 Gastric Inhibitory Peptide (GIP) is one of the major gastrointestinal 
hormones.  Released from the intestinal mucosa in response to fat and glucose, GIP 
acts to inhibit gastric secretion and stimulate insulin release GIP also acts as an 
antagonist to CCK by inhibiting intestinal motility and gastric emptying (Johnson, 
2001).  While some hormones like gastrin and motilin act to increase gastric 
contractions; GIP, secretin and the hormone somatostatin act to inhibit gastric 
contractions (Preston, 1985).  Similar to GIP is the gut peptide hormone GLP-1, also 
known as glucagon like peptide hormone (Hellstrom, 2009).  A study conducted in 
2009 in Sweden by Hellstrom et al., looked at incretin hormones such as GLP-1 and 
their effect on gut motility and symptomatic IBS (Hellstrom, 2009).  The study 
concluded that GLP-1 acted as an inhibitory hormone on small bowel motility via 
vagal pathways in both controls and patients suffering from IBS (Hellstrom, 2009).   
The study concluded that incretin hormones, such as GIP and GLP-1, may be of 
clinical significance to understanding many of the gut motility disorders such as IBS 
(Hellstrom, 2009). 
 
MOTILIN 
 Motilin, discovered in the 1970s, is a small intestine hormone composed of 
22 amino acids arranged in a linear fashion (Johnson, 2001).    This hormone plays a 
crucial role in the gut.  The cyclical release of motilin is responsible for upper 
gastrointestinal motility (Johnson, 2001).   Motilin is a major hormone in the 
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connection between the central nervous system and the peripheral nervous system.  
Motilin’s release, just like gastrin, is under neurological control, and is responsible 
for the interdigestive migrating myoelectric complex that moves through the 
stomach and small bowel every ninety minutes (Miller et al., 1999).   
 Phase III of the migrating myoelectric complex is the most active phase of the 
cycle.  During this phase, bursts of contractions stimulated by motilin originate in 
the antrum and the duodenum and then migrate distally (Miller et al., 1999).  
Although motilin is under neurological control, it acts directly on the smooth muscle 
of the intestine (Miller et al., 1999).  The actions of motilin are so potent and 
directed that motilin now represents the strongest hormonal stimulus for gastric 
contractions (Miller et al., 1999).  This finding opens up a world of causes and 
treatments for patients suffering from gastrointestinal motility disorders (Miller et 
al., 1999).  High levels of motilin have been associated with abnormal increases of 
gut activity and researchers have found abnormally high levels of motilin in patients 
suffering from IBS (Palsson et al., 2013).   
 
Concluding the Gastrointestinal Hormones 
These give gut hormones, secretin, gastrin, GIP, CCK and motilin provide a 
much deeper understanding as to what is controlling many of the intestinal 
functions.  We will now look into the role some of the ovarian hormones might play 
throughout the intestine, as well as take a deeper look into many of their 
interactions with other hormones.  Keep in mind the importance each gut hormone, 
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secretin, gastrin, CCK, GIP and motilin, and their potential effects on the underlying 
mechanisms associated with IBS symptoms such as constipation, diarrhea, bloating, 
and abdominal pain. 
 
 
The Ovarian Hormones  
 As previously stated, women are twice as likely to suffer from IBS than men 
(Chang et al., 2006).  This disparity could be attributed to one of the key differences 
between men and women: their gonadal hormones.  IBS symptoms in women tend 
to emerge at the time of gonadal maturation, when the follicle stimulating hormone 
(FSH), luteinizing hormone (LH), estrogen and progesterone begin to be excreted 
throughout the body at much higher levels (Heitkemper et al., 2008).   In order to 
better understand how these sex hormones play a role in symptomatic IBS, it is 
important to take a deeper look at the menstrual cycle and the effects of the ovarian 
hormones, estrogen and progesterone, on gastrointestinal symptoms.  Studies have 
been performed suggesting that women diagnosed with IBS and IBD suffer from 
cyclic pain fluctuations, suggesting that female gonadal hormones play a role in the 
modulation of painful signal processing (Ji et al., 2008). 
 The average length of a woman’s menstrual cycle is 28 days.  During this 
period of time, the four main female sex hormones, FSH, LH, estrogen and 
progesterone rise and fall in a cyclical manner.  Figure 11 shows the hormonal 
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fluctuations that occur throughout the menstrual cycle (Smith, 2009)10: 
Figure 11. Hormone Fluctuations throughout the Menstrual Cycle 
 
Figure 11 represents the pattern of hormonal fluctuations that occurs throughout 
the menstrual cycle.  Levels of LH and FSH remain fairly low and then spike around 
day fourteen of the menstrual cycle so that ovulation can occur (Smith, 2009).  
                                                          
10 Smith MS. (2009). Estrus and menstrual cycles: neuroendocrine control. Encyclopedia of 
Neuroscience. Pages 1-5. 
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Levels of estradiol and estrus, forms of the ovarian sex hormone estrogen, are 
elevated during the follicular phase and drop dramatically once ovulation has 
occurred (Smith, 2009).  Progesterone, the other very important ovarian hormone 
other than estrogen, is the only hormone in the above schematic that has increased 
levels during the luteal phase of the menstrual cycle (Smith, 2009).  Once the 
menstrual cycle occurs, the levels of progesterone drop dramatically, rising again in 
a cyclical manner following ovulation during the luteal phase (Smith, 2009).   
Both estrogen and progesterone, secreted from the ovaries, do not just affect 
cells directly around the ovaries (Nelson et al., 2001).  These hormones are released 
into the blood stream, allowing them to act on various organs and cells by either 
inhibiting or stimulating their functions (Palsson et al., 2013).   There are many 
other sites throughout both men and women that estrogen and progesterone can 
modulate, such as those within the vascular endothelial and smooth muscle cells 
(Nelson et al., 2001).   
 
 
Ovarian Hormone Fluctuations and Gastrointestinal Symptoms 
Receptors for both progesterone and estrogen have been found on 
gastrointestinal cells (Palsson et al., 2013).   This finding suggests that the ovarian 
hormones are designed to influence the gastrointestinal tract, and that the 
fluctuations in IBS symptoms that seem to correlate to the cyclic hormonal 
fluctuations during the menstrual cycle, are not a coincidence  (Palsson et al., 2013).   
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A study conducted by Jackson et al. published in the Journal of Gastroenterology 
found that female IBS patients suffered from greater sensitivity to rectal distention 
during the perimenstrual period, the period of time two weeks prior to the start of 
menses (Jackson et al., 1997).  Other studies have found that the IBS symptom of 
bloating tends to be exacerbated during the luteal phase, suggesting that 
progesterone, the only hormone prominent during this phase, may play a role in 
modulating the symptoms of IBS  (Palsson et al., 2013).    
Congruent with these findings, a study conducted by Hapidou et al., found 
that women have a much lower pain threshold during the luteal phase, when 
progesterone is elevated, as compared to the follicular phase (Hapidou et al., 1988).  
Balloon distention studies have also found that women who suffer from IBS have 
cyclical increases in gut pain sensitivity, further suggesting a hormonal role in the 
fluctuations of IBS symptom severity (Palsson et al., 2013).   Gastrointestinal transit 
time has been found to be markedly slow during the luteal phase as compared to the 
follicular phase in women suffering from IBS (Heitkemper et al., 2001).  Pre-
menopausal women have also been shown to have slower gastric emptying as 
compared to post-menopausal emptying, suggesting that estrogen and/or 
progesterone plays a role in inhibiting gastric emptying (Heitkemper et al., 2001).     
In addition to the influence estrogen and progesterone have been found to 
have over the visceral pain experienced by women suffering from IBS, changes in 
autonomic nervous system function and/or balance have been found in 
approximately 33% of patients suffering from IBS.  The autonomic nervous system 
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(ANS) is comprised of the parasympathetic nervous system; which includes the 
ovarian hormones estrogen and progesterone, and sympathetic nervous system.  
The ovarian hormones estrogen and progesterone are mediated and controlled by 
the autonomic nervous system, and patients suffering from severe IBS symptoms 
may also be suffering from an imbalance in efferent fibers to the gut (Heitkemper et 
al., 2001).  These ANS imbalances may be contributing to alterations in 
gastrointestinal symptoms such as gut motility, constipation, diarrhea, muscle tone, 
secretion, visceral sensitivity and luminal distention (Heitkemper et al., 2001).  The 
association between ANS imbalances and IBS symptoms provides further evidence 
that hormonal fluctuations play a large part in the symptomatic fluctuations seen in 
patients suffering from IBS.   
 
 
IBS Symptoms During Pregnancy and Menopause 
 Pregnancy provides another model in which to look at the effects of ovarian 
hormones on IBS symptoms.  Progesterone, a hormone that is usually only elevated 
during the luteal phase of the menstrual cycle in women, plays a large role during 
pregnancy.  Progesterone, a hormone essential for a healthy pregnancy, begins to 
rise dramatically once pregnancy occurs and remains elevated during the course of 
pregnancy (Druckmann et al., 2005).  Progesterone works to build the endometrial 
lining, an essential step for the implantation of the fertilized egg (Druckmann et al., 
2005).  The elevated progesterone levels during pregnancy are congruent with the 
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exacerbated gastrointestinal symptoms that occur in IBS patient throughout the 
course of pregnancy.   
 In a study examining the effect of progesterone on colonic smooth muscle in 
canines showed that progesterone reduced the force of contractions in both the 
longitudinally and circulatory oriented strips of smooth muscle, as well as the 
frequency of contractions in the longitudinally oriented strips of smooth muscle 
(Gill et al., 1985).  Constipation is one of the most common complaints during 
pregnancy, in which women experience symptoms consisting of infrequent 
defecation, hard and/or pellet like stool, and excessive straining that can often lead 
to external hemorrhoids (Prather, 2004).  Progesterone, shown to exert an 
inhibitory effect on colonic smooth muscle in the study focusing on colonic smooth 
muscle (Gill et al., 1985), could account for many of the IBS-like symptoms such as 
cramping and constipation, known to be exacerbated during pregnancy, a time 
when the hormone progesterone is abnormally elevated in women.  
Baron et al. concluded that the changes occurring throughout the 
gastrointestinal tract during pregnancy, such as alterations in gastric motor function 
and decreases in small-bowel colonic transit, causing bloating and constipation, are 
in response to the elevated levels of hormones (Baron et al., 1993).  This finding 
further links the ovarian hormones, particularly progesterone, to the exacerbated 
gastrointestinal symptoms; suggesting that the hormone progesterone plays a large 
role in modulating, stimulating, and enhancing the gastrointestinal symptoms of IBS.  
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 Constipation, a very serious and clinical problem associated with slow 
colonic transit, affects close to 20% of the US population and is seen primarily 
within the female population (Gonenne at al., 2006).  These symptoms often begin 
during at menarche, when women experience their first menstrual period, and are 
relieved once menstruation begins when levels of progesterone and estradiol levels 
dramatically drop resulting in looser stools (Gonenne at al., 2006).  Pregnancy, a 
period of time when these two hormones, progesterone and estradiol are markedly 
elevated, also represents a period of time during when women experience 
exacerbated levels of constipation and cramping (Gonenne at al., 2006).  Women 
have been shown to have prolonged orocecal transit time, a measure of the gastric 
and small intestine transit speed, during the luteal phase of the menstrual cycle as 
well as the second and third trimesters of pregnancy, times when progesterone 
levels are greatly elevated (Gonenne at al., 2006).   
While an increase in IBS-like symptoms has been shown to occur during the 
luteal phase of the menstrual cycle and during pregnancy when progesterone levels 
are high, a decline in IBS-like symptoms has been indicated following menopause, 
when the ovaries’ production of estrogen and progesterone decrease dramatically 
(Palsson et al., 2013).  
 42 
The Interplay Between the Gut Hormones and Progesterone 
 Although there has been little research done on the role the gut hormones 
secretin, gastrin, CCK, gastric inhibitory peptide, and motilin might play in IBS, there 
is reason to believe that the oscillating levels of these hormones, as well as their 
interactions with progesterone, may explain the fluctuating symptoms of IBS.   
A study focusing on the effect of female sex hormone supplementation and 
withdrawal on colonic transit time within a postmenopausal female population 
suggested that the upregulation of progesterone is associated with G protein 
receptor disorders (Gonenne et al., 2006).  G proteins, proteins associated with the 
contractions and relaxations of smooth muscles, are known to play a major role in 
patients suffering from severe constipation (Gonenne et al., 2006).  The 
overexpression of progesterone receptors in conjunction with elevated levels of 
progesterone causes an upregulation of G proteins, increasing the hormone 
vasoactive inhibitory peptide (VIP), a prominent hormone responsible for inhibiting 
smooth muscle contractions (Cheng et al., 2010).  The link between progesterone, G 
proteins and VIP may provide a possible mechanism for progesterone’s role as a 
possible constipation inducer (Gonenne et al., 2006).   
CCK and motilin are both hormones that initiate gastrointestinal activity and 
contractions following a meal (Palsson et al., 2013).   Following a meal it is normal 
to have CCK and motilin initiate intestinal contractions, but many people who suffer 
from IBS have exacerbated symptoms of constipation and cramping following a 
meal, suggesting that there may be something else affecting CCK and motilin 
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(Palsson et al., 2013).  A study comparing the levels of motilin and the levels of 
progesterone found in pregnant women during the first, second and third trimesters 
as well as post-birth, found that progesterone and motilin levels were indirectly 
proportional (Qiu, 1993).  Plasma motilin and serum progesterone levels were 
measured in a 180 women throughout pregnancy as well as 3-5 days following 
delivery (Qiu, 1993).  A negative correlation was found between these two 
hormones, when progesterone levels were elevated during the late stages of 
pregnancy, levels of motilin were decreased (Qiu, 1993).  When levels of 
progesterone dropped immediately following delivery, levels of motilin were 
markedly increased (Qiu, 1993).   This study suggests that progesterone has a 
dominant and inhibitory effect on motilin.  High levels of motilin and CCK have also 
been found in patients suffering from IBS, suggesting that the increased levels of 
these hormones are a compensatory mechanism within the gut attempting to 
overcome the inhibitory affects progesterone plays on intestinal activity (Palsson et 
al., 2013).   
It has been previously suggested that altered levels of gut hormones may 
play a role in the symptoms associated with functional gastrointestinal disorders 
(Preston et al., 1985).  This paper suggests that it is the hormone progesterone that 
influences these altering levels.  A study looking at motilin, pancreatic polypeptide 
and gastrin concentrations in relation to progesterone fluctuations in forty patients 
with functional bowel disease found a significant correlation between the 
fluctuations in the hormone progesterone to those of the intestinal tract (Preston et 
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al., 1985).  This study found that the patients who experienced constipation and 
slow transit time had much lower levels of motilin, levels that correspond to 
increases in levels of progesterone (Preston et al., 1985).  Progesterone has also 
been suggested as a possible gastrin inhibitor, and patients from this study with low 
levels of gastrin were found to have markedly increased symptoms of constipation, 
further elaborating on progesterone’s role as an inducer, causing fluctuations in the 
various gut hormones; hormones that could very well be causing many of the 
symptoms associated with painful IBS (Preston et al., 1985). 
 
 
Discussion 
Irritable Bowel Syndrome, one of the most confusing and variable functional 
bowel disorders, has become an extremely burdensome syndrome in medicine.  
Because IBS cannot be diagnosed based upon biological parameters, IBS is now 
diagnosed by the presence of specific symptoms (Oberndorff-Klein, 2004), an often 
tumultuous guessing game that leaves many physicians bewildered and patients 
without answers.   Because many of these symptoms can often resemble those of 
other diseases, the diagnosis of IBS can prove to be quite difficult.   
Diagnosing IBS now occurs based on exclusion criteria, much due to the fact 
that no clear or defined cause has been found.  The National Institute of Health 
recognizes six potential causes that are currently being studied by researchers.  The 
potential causes of IBS include, brain-gut signaling problems, colon muscle 
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dysfunction, hypersensitive nerves in the gut, bacterial infections, and the 
overgrowth of intestinal bacteria 
(http://digestive.niddk.nih.gov/ddiseases/pubs/ibs_ez/. 2011).   This thesis has 
attempted to create a model based on hormone fluctuations in both the intestinal 
tract and throughout the systemic system.  This model focuses on hormone 
fluctuations in relation to some of the many symptoms of IBS.  Based on the Rome 
Criteria, the gold-standard and must used criteria for IBS, a diagnosis of IBS is 
proposed when the patient’s symptoms have been present for at least six months, 
abdominal pain or discomfort has been present for at least three days every month 
for the last three months, and that the abdominal pain or discomfort has two or 
three specific defining features (Corazziari, 2004).  
 The Mayo Clinic addresses the fact that although IBS is a chronic condition, 
the signs and symptoms associated with this disorder often fluctuate.  The Mayo 
Clinic defines IBS is a multifactorial syndrome brought upon by a combination of 
both environmental and genetic determinants 
http://www.mayoclinic.com/health/paragard/MY00997, 2012).  Current literature 
does not provide a model as to why many patients experience drastic fluctuations in 
their symptoms, and due to these fluctuations, providers have had a difficult time 
providing treatment to their patients.  The model of progesterone, one of the 
hormones influencing stress throughout the body and an ovarian hormone much 
more pronounced in women than in men, as a key regulator of the symptoms 
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associated with IBS provides a novel mechanism behind the clear fluctuations in 
symptoms.  
Treatments for IBS have not proven to be too beneficial.  Because this 
syndrome is not understood on the pathologic level, the therapies prescribed are 
usually targeted to relieve individual symptoms (Camilleri et al., 2009).  It is 
important to attempt to develop therapies that target the underlying mechanisms of 
painful IBS rather than just targeting the symptoms (Trinkley et al., 2010) so that 
we can create novel therapies that are causally directed, improving gastrointestinal 
function and health (Anderson et al., 2011). 
It is important to look at this syndrome from an epidemiologic perspective. 
The prevalence of women who suffer from this syndrome as compared to men is 
much more pronounced (Makhari, 2011).  In fact, women are twice as likely to 
suffer from IBS than men (Chang et al., 2006).  Not only do women suffer more from 
IBS than men, but women with IBS are more likely to report dysmenorrhea and 
premenstrual distress syndrome as compared to women who do not suffer from IBS 
(Heitkemper et al., 2006).   This may suggest that there is a connection between the 
pain experienced during IBS and the hormones that surge throughout the menstrual 
cycle.  Although the gender related differences seen in IBS are likely multifactorial 
involving environmental, psychological, genetic and biological factors, the event of 
gonadal maturation coinciding with the onset of painful IBS symptoms suggests that 
these two events are not independent (Heitkemper et al., 2008).   
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Gastrointestinal transit time has been found to be markedly slowed during 
the luteal phase of the menstrual cycle, when the hormone progesterone is 
dramatically elevated, as compared to the follicular phase in women suffering from 
IBS, suggesting that the hormone progesterone has a profound effect on the 
gastrointestinal symptoms associated with IBS (Heitkemper et al., 2001).  
Progesterone is also markedly increased during the second and third trimesters of 
pregnancy, and these elevated levels during pregnancy are congruent with the 
exacerbated gastrointestinal symptoms, such as constipation and cramping, that 
often occur in IBS patient throughout the course of their pregnancy (Druckmann et 
al., 2005).   
Constipation, a very serious and clinical problem associated with slow 
colonic transit, affects close to 20% of the US population and is seen primarily 
within the female population (Gonenne at al., 2006).  These symptoms often begin 
during at menarche, when women experience their first menstrual period, and are 
relieved once menstruation begins when levels of progesterone and estradiol levels 
dramatically drop resulting in looser stools (Gonenne at al., 2006).  While an 
increase in IBS-like symptoms has been shown to occur during the luteal phase of 
the menstrual cycle and during pregnancy when progesterone levels are high, a 
decline in IBS-like symptoms has been indicated following menopause, when the 
ovaries’ production of estrogen and progesterone decrease dramatically (Palsson et 
al., 2013), further suggesting progesterone’s role in modulating the gastrointestinal 
symptom fluctuations found in patients suffering from IBS. 
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This thesis takes a deeper look into the possible mechanisms behind 
progesterone’s influence over the gastrointestinal symptoms by evaluating its 
relationship with secretin, gastrin, CCK, gastric inhibitory peptide, and motilin; the 
prominent hormones found throughout the gastrointestinal tract.  One possible 
mechanism looks at progesterone’s effects on G proteins and the hormone, 
vasoactive inhibitory peptide also known as VIP.  It was concluded that an 
overexpression of progesterone receptors in conjunction with elevated levels of 
progesterone may cause an upregulation of G proteins, thereby increasing the 
hormone vasoactive inhibitory peptide (VIP), a prominent hormone responsible for 
inhibiting smooth muscle contractions (Cheng et al., 2010).  This link may provide a 
possible mechanism for progesterone’s role in inducing constipation and cramping 
(Gonenne et al., 2006).   
High levels of progesterone were found to correspond to low levels of 
motilin, a hormone responsible for inducing gastrointestinal activity following a 
meal, suggesting that progesterone has a dominant and inhibitory effect over the 
gastrointestinal hormone motilin (Qiu, 1993).  Inhibiting motilin, a hormone that 
along with CCK initiates gut contractions, could cause the severe constipation and 
cramping associated with IBS. 
Progesterone has also been suggested as a possible gastrin inhibitor, and 
patients from this study with low levels of gastrin were found to have markedly 
increased symptoms of constipation, further elaborating on progesterone’s role as 
an inducer, causing fluctuations in the various gut hormones; hormones that could 
 49 
very well be causing many of the symptoms associated with painful IBS (Preston et 
al., 1985). 
Studies that looked a the correlation between progesterone and some of the 
gut hormones such as VIP, motilin and gastrin provide possible mechanisms 
underlying progesterone’s dominant role in modulating and inducing many of the 
symptoms associated with IBS.  Many of the fluctuations associated with patients’ 
symptoms correspond to the fluctuations in progesterone levels seen during the 
menstrual cycle, throughout pregnancy and post-menopause when the levels are 
dramatically reduced.  Looking at progesterone and its effects on the intestinal 
hormones and symptom fluctuations will allow providers to provide better and 
more directed therapies for patients suffering from IBS.  
 
 
Future Research for Effective Therapies 
In order to provide relief for these patients, much more research is needed in 
order to understand the underlying mechanisms associated with these symptoms.  
Treatments should be targeted towards the mechanisms associated with causing 
these symptoms rather than targeted to the symptoms themselves at a very 
superficial level.  Looking at progesterone as a possible hormone that potentially 
induces and/or exacerbates many of the symptoms associated with IBS and IBD 
could provide a novel approach to target therapeutic agents.  
 50 
 A possible course of treatment to provide relief that is also targeted towards 
a potential mechanism could be to place women suffering from severe IBS-like 
symptoms on hormone replacement therapy such as estrogen and progesterone or 
just progesterone.  This way, the spikes in progesterone that may induce 
constipation and cramping would be eliminated, providing much sought after relief 
for the patient.  Therapies should be researched that act as progesterone receptor 
antagonists localized in the gut.  This kind of therapy would also alleviate many of 
the symptoms associated with increased levels of progesterone or progesterone 
receptors throughout the intestinal tract.    
 Irritable Bowel Syndrome and Inflammatory Bowel Disease remain as two of 
the most mysterious and convoluted diseases.  It is important to look into the 
mechanisms behind the problems associated with these diseases in order to better 
treat the hundreds of thousands of individuals that suffer every day from these 
conditions.  Progesterone as well as other hormones, and their interactions with the 
gut should be further evaluated in order to continue to better understand these 
conditions and help those suffering. 
 
 51 
REFERENCES 
Abraham C, Cho J. (2009). Mechanisms of disease: Inflammatory bowel disease. New 
England Journal of Medicine. Vol 361:2066-2078. 
 
Andresen V, Keller J, Pehl C, Schemann M, Preiss J, Layer P. (2011). Irritable bowel 
syndrome- the main recommendations. Deutsches Ätzteblatt International. 
Vol 108(44), 751-760. 
 
Baron T, Ramirez B, Richter JE. (1993).  Gastroinestinal motility disorders during 
pregnancy. Annals of Internal Medicine. Vol 118(5): 366-375.  
 
Behar, J. (2009). Role of progesterone in colonic muscle dysfunction. Research Grant 
Database. 
 
Bernstein MT, Graff LA, Targownik LE, Downing K, Shafer LA, Rawsthorne P, 
Bernstein CN, Avery L. (2012). Gastrointestinal symptoms before and during 
menses in women with IBD. Alimentary Pharmacology and Therapeutics. Vol 
36 (135-144). 
 
Bjornsson B, Orvar KB, Theodors A, Kjeld M. (2006). The relationship of 
gastrointestinal symptoms and menstrual cycle phase in young healthy 
women. Laeknabladid. Vol 92.10 (677-682). 
 
Bommelaer G, Poynard T, Le Pen C, Gaudin AF, Maurel F, Priol G, Amouretti M, 
Frexinos J, Ruszniewski P, El Hasnaoui A. (2004). Prevalence of irritable 
bowel syndrome (IBS) and variability of diagnostic criteria. 
Gastroentérologie Clinique et Biologique. Vol 28 (554-561). 
 
Camilleri M, Andresen V. (2009). Current and novel therapeutic options for irritable   
bowel syndrome management. Digestive and Liver Disease. Vol 41, 854-862. 
 
Chang L, Toner BB, Fukudo S, Guthrie E, Locke GR, Norton NJ, Sperber AD. (2006). 
Gender, age, society, culture, and the patient’s perspective in the functional 
gastrointestinal disorders. Gastroenterology. Vol 130.5 (1435-1446). 
 
Cheng L, Biancani P, Behar J. (2010). Progesterone receptor A mediates VIP 
inhibition of contraction. American Journal of Physiology. Gastrointestinal 
and Liver Physiology. 298(3):G433-9. 
 
ChemBlink. (2013). Online database for chemicals around the world. Secretin. 
http://www.chemblink.com/products/17034-35-4.htm.  
 
 52 
Corazziari, E. (2044). Definition and epidemiology of functional gastrointestinal 
disorders. Best Practice & Research Clinical Gastroenterology. Vol 18(4), 
613-631. 
 
d’Arcangues, C. (2007). Worldwide use of intrauterine devices for contraception. 
Development and Research Training in Human Reproduction, World Health 
Organization, CH-1211. 
 
Drossman, D. (1999). Do psychosocial factors define symptom severity and patients 
status in irritable bowel syndrome? American Journal of Medicine. Vol 
107(5), 41-50. 
 
Druckmann R, Druckmann MA. (2005). Progesterone and the immunology of 
pregnancy. Journal of Steroid Biochemistry and Molecular Biology. Vol 97(5): 
389-396. 
 
Fortney, JA, Feldblum, PJ, Raymond EG. (1999). Intrauterine devices. The optimal 
long-term contraceptive method? Journal of Reproductive Medicine. Vol 
44(3):269-74. 
 
Gill RC, Bowes KL, Kingma YJ. (1985). Effect of progesterone on canine colonic 
smooth muscle. Gastroenterology. Vol 88.6 (1941-7). 
 
Giamberardino MA, Berkley KJ, Lezzi S, de Bigontina P, Vecchiet L. (1997). Pain 
threshold variations in somatic wall tissues as a function of menstrual cycle, 
segmental site and tissue depth in non-dysmenorrheic women, 
dysmenorrheic women and men. Pain. Vol 71(2), 187-197. 
 
Gonenne J, Esfandyari T, Camilleri M, Burton DD, Stephens DA, Baxter KL, 
Zinsmeister AR, Bharucha AE. (2006). Effect of female sex hormone 
supplementation and withdrawal on gastrointestinal and colonic transit in 
postmenopausal women. Neurogastroenterol and Motility. Vol 18 (911-918). 
 
Hapidou EG, DeCatanzaro. (1988). Sensitivity to cold pressor pain in dysmenorrheic 
and non-dysmenorrheic women as a function of menstrual cycle phase. 
Journal of Pain. Vol 34: 277-283. 
 
Heitkemper M, Chang L. (2009). Do fluctuations in ovarian hormones affect 
gastrointestinal symptoms in women with irritable bowel syndrome? Gender 
Medicine. Vol 6, Theme Issue (152-167). 
 
Heitkemper M, Jarrett M. (2001). Gender differences and hormonal modulation in 
visceral pain. Current Pain and Headache Reports. Vol 5 (35-43). 
 53 
Heitkemper M, Jarrett M. (2008). Irritable bowel syndrome: does gender matter? 
Journal of Psychosomatic Research. Vol 64 (583-587). 
 
Heitkemper M, Jarrett M. (2008). Update on irritable bowel syndrome and gender 
differences. Nutrition in Clinical Practice. Vol 23( 3):275-283. 
 
Hellstrom PM. (2009). GLP-1: broadening the incretin concept to involve gut 
motility. Regulatory Peptides. Vol 156(1-3): 9-12. 
 
Holst N, Jenssen TG, Burhol PG, Haug E, Forsdahl F. (1989). Plasma gastrointestinal 
hormones during spontaneous and induced menstrual cycles. The Journal of 
Clinical Endocrinology & Metabolism. Vol 68(6):1160-1166. 
 
Hungin APS, Whorwell PJ, Tack J, Mearins F. (2002). The prevalence, patterns and 
impact of irritable bowel syndrome: an international survey of 40,000 
subjects. Alimentary Pharmacology and Therapeutics. Vol 17, 643-650. 
 
Jackson NA, Houghton LA, Whorwell PJ, Lea R. (1997). The menstrual cycle affects 
rectal visceral sensitivity in patients with irritable bowel syndrome (IBS) but 
not healthy volunteers. Journal of Gastroenterology. Vol 112(A):11-32. 
 
Ji Y, Tand B, Traub RJ. (2008). The visceromotor response to colorectal distention 
fluctuates with the estrous cycle in rats. Journal of Neuroscience. Vol 154(4): 
1562-1567. 
 
John Hopkins Medicine of Gastroenterology and Hepatology. (2001-2013). Irritable 
bowel syndrome (IBS): therapy.  
http://www.hopkinsgi.org/GDL_Disease.aspx?CurrentUDV=31&GDL_Cat_ID=
AF793A59B73642CB9E1FE79D2B9FC358&GDL_Disease_ID=F5E21D6B-
A88E-44F9-900F-7E295C50D38B. 
 
Johnson, LR. Gastrointestinal physiology.  (2001). The Mosby Physiology Monograph 
Series. 6th Edition. 
 
Kaneshiro B, Aeby T. (2010). Long-term safety, efficacy, and patient acceptability of 
the intrauterine Copper T-308A contraceptive device. International Journal 
of Womens Health. 2:211-20. 
 
Karat D, Brotherick I, Shenton BK, Scott D, Raimes SA, Griffin SM. (1999). Expression 
of oestrogen and progesterone receptors in gastric cancer: a flow cytometric 
study. British Journal of Cancer. Vol 80(8):1271-1274. 
 
 54 
Lam C, Spiller R. (2011). The shifting interface between IBS and IBD. Current 
Opinion in Pharmacology. Vol 6(11):586-592 
 
Lu SS, Lau CP, Tung YF, Huang SW, Chen YH, Shih HC, Tsai SC, Lu CC, Wang SW, Chen 
JJ, Chien EJ, Chien CH, Wang PS. (1996). Lactate stimulates progesterone 
secretion via an increase in cAMP production in exercised female rats. 
American Journal of Physiology. Endocrinology and Metabolism. Vol 271: 
E910-E915. 
 
Makharia GK, Verma AK, Amarchand R, Goswarmi A, Singh P, Agnihotri A, Suhail F, 
Krishnan A. (2011). Prevalence of irritable bowel syndrome: a community 
based study from northern India. Journal of Neurogastroenterology and 
Motility, Vol 17(1):82-7. 
 
Mayo Clinic. (2011). Definition, IBS.   http://www.mayoclinic.com/health/irritable-
bowel-syndrome/DS00106/. August 15, 2012. 
 
Mayo Clinic. (2011). Paraguard, Copper IUD.   
http://www.mayoclinic.com/health/paragard/MY00997. April 2, 2012. 
 
Miller P, Roy A, St-Pierre S, Dagenais M, Lapointe R, Poitra P. (1999). Motilin 
receptors in the human antrum. Neuroregulation and Motility. American 
Journal of Physiology: Gastroinestinal and Liver Physiology. Vol 278:18-23. 
 
Morgan, KW. (2006). The Intrauterine Device: Rethinking Old Paradigms. Journal of 
Midwifery & Women’s Health, Vol 51(6):464-70. 
 
National Institute of Health. What I need to know about irritable bowel syndrome. 
http://digestive.niddk.nih.gov/ddiseases/pubs/ibs_ez/. December 15, 2011. 
 
Nelson LR, Bulun SE. (2001). Estrogen production and action. Journal of the 
American Academy of Dermatology. Vol 45(3):116-124. 
 
Occhipinto K, Smith J. (2012). Irritable bowel syndrome: a review and update. 
Clinics in Colon and Rectal Surgery. Vol 1:46-52. 
 
Oberndorff-Klein AH, Brummer R-JM, de Wit NJ, Muris JWM, Stockbrugger RW. 
(2004). Irritable bowel syndrome in general practice: an overview. 
Scandinavian Journal of Gastroenterology. Vol 39(241):17-22. 
 
Palsson O, Whitehead W. (2013). Hormones and IBS. UNC Center For Functional GI 
& Motility Disorders. http://www.med.unc.edu/ibs/files/educational-gi-
handouts/IBS%20and%20Hormones.pdf/view.  
 55 
 
Papa A, Danese S, Grillo A, Gasabarrini G, Gasabarrini A. (2003). Review article: 
inherited thrombophilia in inflammatory bowel disease. American Journal of 
Gastroenterology. Vol 98(6):1247-51. 
 
Payne, S. (2004). Sex, gender, and irritable bowel syndrome: making the 
connections. Gender Medicine. Vol 1:1-11.  
 
Pfaffl MW, Lange IG, Meyer HH. (2003). The gastrointestinal tract as target of steroid 
hormone action: quantification of steroid receptor mRNA expression (AR, 
Era, ERb and PR) in 10 bovine gastrointestinal tract compartments by kinetic 
RT-PCR. Journal of Steroid Biochemistry & Molecular Biology. Vol 84:159-
166. 
 
Prather, CM. (2004). Pregnancy-related constipation. Current Gastroenterology 
Reports. Vol 6(5): 402-404. 
 
Preston DM, Adrian TE, Christofidas ND, Lennard-Jones JE, Bloom SR. (1985). 
Positive correlation between symptoms and circulating motilin, pancreatic 
polypeptide and gastrin concentrations in functional bowel disorders. Gut. 
Vol 26(10):1059-1064. 
 
Qui XH. (1993). Relation between motilin concentration and progesterone level in 
normal pregnancy and early postpartum. Zhonghua Fu Chan Ke Za Zhi. Vol 
28(9): 524-526, 568. 
 
Quigley EMM, Bytzer P, Jones R, Mearin F. (2006). Irritable bowel syndrome: the 
burden and unmet needs in Europe. Digestive and Liver Disease. Vol 38, 717-
723. 
 
Rai R, Chandra V, Tewari M, Kumar M, Shukla H. (2012). Cholecystokinin and gastrin 
receptors targeting in gastrointestinal cancer. Surgical Oncology. Vol 21:4, 
281-292. 
 
Ramazanzadeh F, Tavakolianfar T, Shariat M, Mashhadi IE. (2012). Short-term 
complications of the Mirena® IUS vs the copper IUD in Muslim women. 
Journal of Family Planning and Reproductive Health Care. 38(2):143. 
 
Smith MS. (2009). Estrus and menstrual cycles: neuroendocrine control. 
Encyclopedia of Neuroscience. Pages 1-5. 
 
Steen R, Shapiro K. (2004). Issues in Current Service Delivery: Intrauterine 
Contraceptive Devices and Risk of Pelvic Inflammatory Disease: Standard of 
 56 
Care in High STI Prevalence Settings. Reproductive Health Matters Journal, 
12(23):136–143. 
 
Stoddard, A. et al. (2011). Efficacy and Safety of Long-Acting Reversible 
Contraception. Division of Clinical Research, Department of Obstetrics and 
Gynecology, Washington University in St. Louis School of Medicine, St. Louis, 
MO. Drugs. 71(8):969-980. 
 
Tait AS, Butts CL, Sternberg EM. (2008). The role of glucocorticoids and progestins 
in inflammatory, autoimmune, and infectious disease. Journal of Leukocyte 
Biology. Vol 84:924-931. 
 
Trinkley KE, Nahata MC. (2010). Treatment of irritable bowel syndrome. Journal of 
Clinical Pharmacy and Therapeutics. Vol 36:275-282. 
 
Tyler, CP. et al. (2012). Health Care Provider Attitudes and Practices Related to 
Intrauterine Devices for Nulliparous Women. Obstetrics and Gynecology, Vol 
119(4):762–771. 
 
Van der Schaar PJ, van Hoboken E, Ludidi S, Masclee AA. (2013). Effect of 
cholecystokinin on rectal motor and sensory function in patients with 
irritable bowel syndrome and health controls. Colorectal Disorders. Vol 
15(1): 29-34. 
 
Wald A, Van Thiel DH, Hoechstetter L, Gavaler JS, Egler KM, Verm R, Scott L, Lester R. 
(1981). Gastrointestinal transit: the effect of the menstrual cycle. 
Gastroenterology. Vol 80(6):1497-500. 
 
Welsh, A. (2005).  Long-acting Reversible Contraception: The Effective and 
Appropriate Use of Long-Acting Reversible Contraception. Published by 
RCOG Press at the Royal College of Obstetricians and Gynecologists. Pp 38-
61. 
 
Wirth MM, Meier EA, Fredrickson BL, Schultheiss OC. (2006). Relationship between 
salivary cortisol and progesterone levels in humans. Biological Psychology; 
Science Direct. Vol 74:104-107.  
 
XH, Q. (1993). Relation between motilin concentration and progesterone level in 
normal pregnancy and early postpartum. Zhonghua Fu Chan Ka Za Zhi. Vol 
28-9 (524-526, 568). 
 
 57 
Xiao ZL, Biancani P, Behar J. (2009). Effects of progesterone on motility and 
prostaglandin levels in the distal guinea pig colon. American Journal of 
Physiology.  Gastrointestinal and Liver Physiology. 297: G886-G893. 
 
 
 
 
 
 
 
  
VITA 
 
 
 
 
 
 
 
 
 
 
                                                                
                             
                                                 
 
 
  
  
 
 
  
  
  
  
 
 
 
                   
     
    
  
 
 
   
  
  
  
 
  
  
  
 
 
 
  
  
  
 
  
 
   
 
  
  
  
 
  
 
  
 
 
 
  
  
  
 
 
  
 
 
 
  
  
  
 
  
  
 
 
 
 
  
  
